References

2018 ESC Guidelines for the diagnosis and management of syncope

10.1093/eurheartj/ehy037 · 2018 · External reference

Vasovagal syncope: An overview of pathophysiological mechanisms

10.1016/j.ejim.2023.03.025 · 2023 · External reference

Epidemiology of Syncope/Collapse in Younger and Older Western Patient Populations

10.1016/j.pcad.2012.11.006 · 2013 · External reference

Evaluation of GFAP/UCH-L1 biomarkers for computed tomography exclusion in mild traumatic brain injury (mTBI)

10.1186/s12245-024-00708-z · 2024 · External reference

Diabetes influences cancer risk in patients with increased carotid atherosclerosis burden

10.1016/j.numecd.2019.11.016 · 2020 · External reference

Correction: Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis

10.1186/s12877-022-03388-7 · 2022 · External reference

Deprescribing in older adults with polypharmacy

10.1136/bmj-2023-074892 · 2024 · External reference

Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study

10.1093/gerona/glv219 · 2016 · External reference

Implications of the medication regimen complexity index score on hospital readmissions in elderly patients with heart failure: a retrospective cohort study

10.1186/s12877-023-04062-2 · 2023 · External reference

Frailty in elderly people

10.1016/s0140-6736(12)62167-9 · 2013 · External reference

Comparison of Incidence, Predictors, and the Impact of Co-Morbidity and Polypharmacy on the Risk of Recurrent Syncope in Patients <85 Versus ≥85 Years of Age

10.1016/j.amjcard.2013.07.041 · 2013 · External reference

Prevalence and impact of polypharmacy in older patients with type 2 diabetes

10.1007/s40520-022-02165-1 · 2022 · External reference

Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials

10.1177/1479164120953625 · 2020 · External reference

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

10.1016/j.jash.2014.01.007 · 2014 · External reference

Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience

10.1016/j.pcd.2020.10.002 · 2021 · External reference

An Investigation of Metabolic Risk Factors and Gut Microbiota in Unexplained Syncope

10.3390/biomedicines12020264 · 2024 · External reference

A Metabolomic Approach to Unexplained Syncope

10.3390/biomedicines12112641 · 2024 · External reference

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

10.1016/0021-9681(87)90171-8 · 1987 · External reference

Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation

10.1111/j.1464-5491.2006.01858.x · 2006 · External reference

Development and Validation of the Medication Regimen Complexity Index

10.1345/aph.1d479 · 2004 · External reference

Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications

10.1007/s40266-020-00796-5 · 2020 · External reference

Differences in youngest-old, middle-old, and oldest-old patients who visit the emergency department

10.15441/ceem.17.261 · 2018 · External reference

Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life

10.1016/j.biopha.2021.112341 · 2021 · External reference

Perspectives of Older Patients on the Complexity of Medication Use

10.1111/jgs.70311 · 2026 · External reference

The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study

10.1093/europace/eus154 · 2012 · External reference

DARWIN-FUP network. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

10.1007/s40618-022-02002-2 · 2023 · External reference

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists

10.1016/j.phrs.2020.105052 · 2020 · External reference

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study

10.1016/j.phrs.2022.106396 · 2022 · External reference

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study

10.1016/j.phrs.2024.107517 · 2024 · External reference

Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet

10.4093/dmj.2018.0259 · 2019 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Stop vasodepressor drugs in reflex syncope: a randomised controlled trial

10.1136/heartjnl-2016-309865 · 2017 · External reference

Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: the DANTE Study Leiden

10.1093/ageing/afv199 · 2016 · External reference

The prevalence of polypharmacy in older Europeans: A multi-national database study of general practitioner prescribing

10.1111/bcp.16113 · 2024 · External reference

Dysregulation of the gut-adipose tissue-liver axis: a possible mechanism behind the relationship between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes

10.1007/s11892-026-01623-8 · 2026 · External reference

Glycometabolic cardiac dysfunction in HFpEF: Lessons from multi-omics studies

10.1016/j.phrs.2025.108032 · 2025 · External reference